ABSTRACT Background. The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was developed to refine fineneedle aspiration (FNA) cytology definitions and improve clinical management. This study evaluates the impact of the BSRTC 5 years after its adoption at a single institution. Results. Fifty-four percent (187/347) of Group 1 patients had a preoperative FNA versus 61 % (777/1278) in Group 2 (p = 0.02). Group 1 FNA results included 3 % nondiagnostic, 48 % benign, 17 % follicular, 13 % suspicious for cancer, and 19 % cancer. Group 2 results included 3 % non-diagnostic, 36 % benign, 9 % follicular, 8 % suspicious for malignancy, 18 % malignant and 26 % AUS/ FLUS. In Group 2, the proportions of benign, follicular and suspicious for malignancy FNAs decreased significantly (p \ 0.05). In Group 2, there were more indeterminate FNA diagnoses overall (30 vs. 43 %; p \ 0.001). The rate of cancer in suspicious for cancer FNA lesions increased from 44 to 65 % (p = 0.07). The AUS/FLUS malignancy rate was 15 %.
Conclusions. Since the adoption of the BSRTC at our institution, the proportion of indeterminate FNAs has increased; however, the diagnostic accuracy of the suspicious for cancer category improved. We recommend periodic review of the utilization and malignancy rates per cytologic category at each institution to help tailor clinical management.
Fine-needle aspiration (FNA) biopsy and cytologic interpretation plays an essential role in the diagnosis and evaluation of thyroid nodules. 1 FNA results can be used to stratify the malignant risk of thyroid nodules and therefore triage patients to appropriate therapy: surgery, repeat biopsy, or observation.
Despite widespread use and clinical utility of FNAs, cytologically indeterminate thyroid nodules continue to present a diagnostic dilemma for clinicians. This results in a large number (10-30 %) of patients undergoing thyroidectomy to obtain a definitive histologic diagnosis. 2, 3 In 2009, the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was released to help refine cytologic definitions and improve communication and clinical management. It recommends that each FNA report begins with one of six general diagnostic categories: non-diagnostic, benign, atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm or suspicious for follicular neoplasm, suspicious for malignancy, or malignant. Before the BSRTC was reported, categories for thyroid cytology typically included non-diagnostic, benign, follicular or Hürthle neoplasms (FN/HN), suspicious for malignancy, and malignant. This terminology and interpretation varied significantly from one laboratory or cytopathologist to the next. 1, [4] [5] [6] [7] The category of follicular neoplasms posed the greatest dilemma as follicular carcinomas look similar on an individual cellular level to benign follicular neoplasm, thus limiting the ability of cytology to accurately diagnose these lesions without tissue architecture demonstrating vascular or capsular invasion. 1, 8 The new cytologic category of AUS/FLUS was meant to encompass a subset of lesions not otherwise easily classified as benign, suspicious or malignant. 1 The additional benefit of creating the AUS/ FLUS category was that follicular neoplasm was then reserved for specimens in which a follicular carcinoma was suspected and should be subsequently triaged to operative intervention. 1 Our institution adopted the BSRTC in February 2009, and after 2 years of use our group published an initial experience with the new classification system as it relates to utilization and malignancy rates for each cytology category. 9 This study evaluates the impact of the BSRTC 5 years after its adoption at a single institution. As a secondary measure, this study serves as an internal review of the malignancy rates of each BSRTC category.
METHODS
After obtaining Institutional Review Board approval, we performed a retrospective review of 1,625 patients who underwent thyroidectomy from July 2007 through September 2013. Among these patients, 964 had a preoperative FNA and are the main focus of this study. Our early institutional experience using the BSRTC included some of these patients. 9 Vanderbilt University's Division of Anatomic Pathology, which includes cytopathology, adopted the BSRTC and implemented its terminology in their reports, starting Information regarding patient demographics, whether FNA was performed, results of FNA biopsy, as well as final histologic diagnoses was collected. Two certified cytopathologists read all the internal thyroid cytology specimens. The majority of outside cytology ([95 %) was reviewed internally. Patients with [1 nodule biopsied or undergoing more than one FNA biopsy at a separate time were classified by the FNA result with the highest estimated risk of malignancy. This occurred in 21 (11 %) patients in the pre-BSRTC era and 98 (12.6 %) patients in the post-BSRTC era. The cytology categories for Group 1 included nondiagnostic, benign, FN/HN, suspicious for malignancy, and malignant. Specimens with the word 'atypia', 'cannot rule out follicular neoplasm', or 'follicular/cellular lesion' present on the FNA cytology report before adoption of the BSRTC were included in the follicular/Hürthle cell classification. The cytology categories for Group 2, detailed fully in the BSRTC, included non-diagnostic, benign, AUS/FLUS, FN/HN, suspicious for malignancy, and malignant.
Indeterminate FNA diagnoses were grouped and analyzed. Indeterminate FNA diagnoses in group 1 included FN/HN and suspicious for malignancy. In Group 2, the categories FN/HN, AUS/FLUS, and suspicious for malignancy were considered indeterminate FNA diagnoses.
The proportion of surgical patients with a preoperative FNA was recorded, as well as the percentage utilization of each cytologic category in those patients. The rates of malignancy of each cytology category were also recorded. A detailed review of the cytology and pathology reports was also conducted in an attempt to exclude incidental cancers not contained within the index nodule.
Statistical analysis was performed using STATA version 13.0 (StataCorp., College Station, TX, USA). Univariate analysis was conducted to compare selected variables using Student's t-test, Chi-square tests, probability testing, and Wilcoxon rank sum. The proportions of each FNA category, malignancy rate per cytologic diagnosis, overall malignancy rate, and rate of indeterminate FNAs were compared. Statistical significance was defined as a p value of \0.05. Missing data were excluded from the analysis.
RESULTS
A total of 1,625 patients underwent thyroidectomy during the study period-347 (21 %) patients in the pre-BSRTC era and 1,278 (79 %) in the post-BSRTC era. Patient demographics, operative indication, and utilization rates of FNA are detailed in Table 1 . There was no significant difference between periods regarding the age of patients. There were more women in the pre-BSRTC era when compared with the post-BSRTC era (84 vs. 79 %; p = 0.025). The most common indication for thyroidectomy was benign disease. Overall, the number of patients going to the operating room for the clinical indication of an indeterminate FNA increased from 17 to 26 %. Fifty-four percent (187/347) of patients in the pre-BSRTC era and 61 % (777/1625) in the post-BSRTC era (p = 0.011) had preoperative FNAs.
The utilization rates of each cytology category in patients undergoing thyroidectomy who had an FNA are detailed in Table 2 . Group 1 FNA results included 3 % non-diagnostic, 48 % benign, 17 % FN/HN, 13 % suspicious for malignancy, and 19 % malignant for an overall indeterminate rate of 30 %. Group 2 results included 3 % non-diagnostic, 36 % benign, 26 % AUS/FLUS, 9 % FN/ HN, 8 % suspicious for malignancy, and 18 % malignant for an overall indeterminate rate of 43 %. There was a significant decrease in the proportion of benign Malignancy rates per cytologic category pre-and post-BSRTC in patients undergoing thyroidectomy are detailed in Table 3 . The rate of cancer in suspicious for malignancy FNA lesions increased from 44 to 65 %; however, this difference failed to reach statistical significance (p = 0.07). The AUS/FLUS malignancy rate in patients undergoing thyroidectomy was 15 %. The overall malignancy rate excluding incidental cancers among patients with an FNA undergoing thyroidectomy was 30 % in both Group 1 and Group 2 (p = 0.9387). The overall rate of malignancy among patients with indeterminate lesions in Groups 1 and 2 was 33 versus 26 %, respectively (p = 0.271).
The final histology of lesions with a preoperative FNA report of AUS/FLUS is detailed in Table 4 . The most common histology in patients with an AUS/FLUS diagnosis and subsequent malignancy was papillary thyroid cancer (13/ (Table 4 ) demonstrated no change in the proportion of benign or malignant follicular lesions (50 % in both time periods), and a non-significant decrease in the proportion of papillary and follicular variant papillary cancers (25-14 %; p = 0.148).
Seventy-six percent of patients undergoing surgery for AUS/FLUS did so without repeat FNA. The rate of malignancy for AUS/FLUS with a repeat FNA was 9 %, whereas for those without a repeat FNA the rate was 18 % (p = 0.239).
DISCUSSION
Since the adoption of BSRTC at this institution, there has been an increase in the proportion of patients who receive a preoperative FNA. This finding was previously described by Sosa et al. who reviewed public and private insurance claims databases to determine the rate of FNAs from 2006 to 2011, and who found that thyroid FNA utilization increased at an annual rate of 16 %. 10 This observation is in part due to increased use of highly sensitive imaging modalities allowing for identification of smaller lesions as well as improved awareness of the utility of FNA in the evaluation of thyroid nodules. The present study also found an apparent increase in the proportion of patients undergoing surgery for indeterminate FNA results. This observation may be attributable to several factors. This is a surgical series and as such patients with benign lesions by FNA who did not undergo thyroidectomy are excluded from the calculated rate of cytology category utilization. In addition, the exclusion of said patients results in a shift away from benign to other categories, including indeterminate. Thus, the increased proportion of patients undergoing surgery for indeterminate lesions may simply be a result of an increased number of patients with benign FNA results avoiding thyroidectomy.
Another explanation for the increased proportion of patients undergoing thyroidectomy with indeterminate FNA results is the addition of the cytology category AUS/ FLUS. In this series there was a decrease in the number of benign, FN/HN, and suspicious for malignancy lesions in the post-BSRTC era. This suggests a possible shift from these categories to AUS/FLUS. This observation may reflect increased comfort reporting findings of AUS/FLUS for lesions that previously would have been described as suspicious for neoplasm or malignancy. The explanation for the decrease in the benign cytology category remains unclear but could represent over-reading by our cytopathologists.
The overall percentage of utilization of AUS/FLUS among patients undergoing thyroidectomy was 26 %, which is higher than recommended by the BSRTC (\7 %). The finding of greater-than-expected utilization of AUS/ FLUS has been described by several other authors and ranges from 2.3-29 %. 5, 9, [11] [12] [13] The etiology of this discrepancy between predicted and actual values remains unclear, but a possible explanation may be that this is a surgical series and as such fails to capture patients who did not go to surgery. In addition, although not documented in our database, rates of lymphocytic thyroiditis, previous biopsy attempts, history of radioactive iodine use and other unknown factors may have influenced/confounded the observed AUS/FLUS rate.
There were no significant differences in the rate of malignancy within cytologic categories in the pre-and post-BSRTC era. However, the rate of cancer in suspicious for malignancy FNA lesions increased from 44 to 65 %. This trend suggests that the addition of AUS/FLUS has resulted in improved categorization of lesions with the presence of nuclear grooves, prominent nucleoli, elongated nuclei and cytoplasm, and/or intranuclear cytoplasmic inclusions in a predominantly benign-appearing sample to AUS/FLUS rather than suspicious for malignancy. 1 Another proposed benefit of creating the AUS/FLUS category was that follicular neoplasm would be reserved for specimens in which a follicular carcinoma is suspected. 1 However, in this study, the final histology distribution in patients with FN/HN lesions demonstrated a decrease in the proportion of papillary and follicular variant papillary cancers (25-14 %; p = 0.148), and no change in the number of follicular lesions (benign or malignant) between time periods (Table 4) . Additionally, the overall cancer rate among FN/HN specimens did not change between time periods (25 vs. 26 %).
Our overall rate of malignancy for AUS/FLUS lesions in this series was 15 %. This is in agreement with the recommended rate of 5-15 % described in the BSRTC. 1 In our initial report, the rate of malignancy in AUS/FLUS was 20 % (first 2 years of experience). As this was higher than recommended, the investigators discussed the findings with their institutional colleagues to increase awareness and promote quality improvement. Additionally, the rate of malignancy in our initial report, and that which continues to be observed in other surgical series (Table 5) , prompted the same investigators to examine the overall malignancy Data are expressed as % (n)
BSRTC Bethesda System for Reporting Thyroid Cytopathology, AUS/ FLUS atypia of undetermined significance/follicular lesion of undetermined significance, FN/HN follicular neoplasm/Hürthle Cell neoplasm rate of all AUS/FLUS lesions in addition to the utility of repeat FNA, not just those who underwent thyroidectomy. This study included 322 patients with the diagnosis of AUS/FLUS from 2009 to 2012 and found the overall utilization and malignancy rate to be 10 and 9.2 %, respectively. Additionally there was no difference in the overall malignancy rate between patients who did or did not undergo repeat FNA (9.9 vs. 8.8 %; p = 0.749), which is in agreement with our current study. 2 Further analysis showed that the malignancy rate for AUS/FLUS was 13.5 % in patients who underwent thyroidectomy, or those who avoided surgery after repeat biopsy ultimately demonstrated benign disease, and 16.5 % when only including surgical patients (p = not significant). Thus, analyzing a surgical series alone, such as the current series, overestimates the risk of malignancy in AUS/FLUS lesions. It does suggest that patients who self-select to surgery or have additional indications for thyroidectomy are more likely to have underlying malignancy (in the index nodule) than those who do not, although the reason is unclear for this association.
The rate of repeat FNA biopsy for AUS/FLUS lesions in the current surgical series was 24 and 33 % in our previously reported overall series. 2 The recommendation in the BSRTC states that repeat biopsy should be performed for AUS/FLUS category lesions, with the caveat that actual management may depend on other factors (e.g. clinical symptoms or sonographic features) not just the FNA interpretation.
1 Information regarding clinical symptoms and sonographic findings was not collected and therefore we were unable to demonstrate the impact of these factors on our overall rate of repeat FNA biopsy for AUS/FLUS lesions. However, it is routine at our institution to recommend repeat FNA biopsy for AUS/FLUS lesions in patients without clinical history, symptoms, or sonographic findings that would otherwise convince us to recommend thyroidectomy. Thus, the low rate of repeat biopsy may indicate that a large proportion of patients with AUS/FLUS lesions either elected to proceed to surgery without repeat biopsy and/or had additional indications for thyroidectomy.
Since the introduction of BSRTC at our institution there has been an apparent change in the rate of malignancy of AUS/FLUS from 20 % in the first 2 years to 15 % over 5 years. The importance of institutional review of cytology to histology correlations to both refine cytopathologic categories and also to accurately reflect the malignancy rates of the different BSRTC categories at each institution cannot be overemphasized. The need for individual institutional review and clinical management based on institutional cancer rates is further highlighted by a recent multi-institutional prospective study by Cibas et al. that analyzed the inter-and intra-observer variability for thyroid nodule cytopathology. This study found the intra-observer variability to be 25.3 %, and the inter-observer variability when comparing central cytopathologists with local pathologists was 36 % when using the six cytology categories as defined by the BSRTC. 14 This study has several limitations. First, any retrospective study is limited by the quality and inconsistency of data in the medical record. Second, as with any evaluation of cytology, there is inter-and intra-observer variability in the report of findings.
14 Third, this study only evaluates patients who eventually underwent operative resection, inherently introducing bias into the analysis. Patients who underwent operative resection likely had other factors such as family history, ultrasound features, etc. that influenced the preoperative probability of malignancy. These confounding factors were not considered in the analysis. However, despite these limitations, the analysis does help to inform thyroid surgeons in their evaluation of the select patient population that has been referred for surgical evaluation. Fourth, as has been previously described, it can at times be difficult to accurately correlate the FNA biopsy sample to a specific nodule on final histology. 6, 7, 15 Efforts were made, while reviewing the records, to determine whether the final histologic diagnosis represented the index nodule. Despite this, we cannot say with certainty that all incidental carcinomas were in fact excluded.
CONCLUSIONS
Five years after the implementation of the BSRTC there remains a large percentage of patients undergoing thyroidectomy for indeterminate cytology, with the majority being AUS/FLUS. Additionally, AUS/FLUS continues to be utilized more frequently than recommended (26 vs. 7 %). However, with continued experience, our multi-disciplinary thyroid group has achieved a malignancy rate of AUS/ FLUS of 15 %, which is within the range recommended by the BSRTC. It remains unclear if this is in fact an overutilization of AUS/FLUS or an accurate representation based on the non-specific criteria. We recommend rigorous cytopathology to histopathology correlation to accurately reflect the malignancy rates of the different BSRTC categories at each institution. Additionally, we recommend communication on an institutional level regarding the rates of malignancy for each cytologic category as clinical management should be tailored to institutional findings.
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